Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd (301126) — Capital Reinvestment Ratio

Latest as of December 2024: 7.78x

Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd (301126) has a Capital Reinvestment Ratio of 7.78x as of December 2024, meaning it reinvests 8% of its operating cash flow (CN¥24.04 Million) in capital expenditures (CN¥187.14 Million). Check how tangible is Hunan Dajiaweikang Pharmaceutical Indust's equity to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

7.78x
Capex / Operating Cash Flow

Operating Cash Flow

CN¥24.04 Million
CNY

Capital Expenditures

CN¥187.14 Million
CNY

Data as of

Dec 2024
Most recent filing

Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd Capital Reinvestment Ratio (2019–2024)

This chart tracks Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd's Capital Reinvestment Ratio across 3 annual periods. For the full cash flow conversion analysis, see 301126 cash flow metrics.

Annual Capital Reinvestment Ratio for Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd (2019–2024)

Year-by-year Capital Reinvestment Ratio for Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd from 2019 to 2024. See Hunan Dajiaweikang Pharmaceutical Indust (301126) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (CNY) Capital Expenditures YoY Change
2024 7.78x CN¥24.04 Million CN¥187.14 Million ▼ -6.8%
2023 8.36x CN¥27.13 Million CN¥226.70 Million ▲ +3394.0%
2019 0.24x CN¥135.91 Million CN¥32.50 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow